It was announced this week that Zosano Pharma, Inc. (Zosano) and Asahei Kasei Pharma (AKP) formed a collaboration to develop Teribone (teriparatide acetate), a transdermal patch treatment for osteoporosis. Zosano, a biopharmaceutical company and an innovator in the field of drug delivery, develops products using its ZP Patch Technology, a transdermal technology that provides efficient delivery using a noninvasive and painless system. AKP, a research-based healthcare innovator, has agreed to develop, market and supply Teribone using its human parathyroid hormone, human PTH 1-34, an osteoporosis treatment for patients with high risk of fracture. Upon the agreement, Teribone uses Zosano’s patented, clinically supported and GMP manufactured ZP Patch Technology to administer AKP’s human PTH (1-34) through the skin. AKP has claimed the exclusive rights to develop and market the transdermal patch product in Japan, Korea, China and Taiwan. Teribone is differentiated through its benefits of self-administration, weekly dosing, room temperature stability, and pain-free delivery without the need for an injection. “AKP and Zosano have joined their world-class and complementary assets to create what we believe has the opportunity to be the best in class product for bone growth in severe osteoporosis patients” said Gail Schulze, Chief Executive Officer of Zosano. “We believe this relationship will provide a product with superior fracture reduction and enhanced patient compliance compared to the currently available PTH injectables to those patients with a high degree of unmet need.” Osteoporosis is a devitalizing disease in which the density and quality of bones are debilitated. An estimated 75 million people are affected in the U.S., Europe and Japan. Bones become fragile and porous with age, and the risk of fracture is greatly increased. Women diagnosed with severe osteoporosis who have had two or more fractures are nine times more likely to fracture than women who have not had a previous fracture. While most osteoporosis treatments are anti-resorptive compounds, which have been shown to only prevent future bone loss, anabolic compounds like ZP PTH have been shown to stimulate bone growth. During Phase II, all ZP-PTH doses were well tolerated with no systemic adverse events. After such positive results, Zosano’s leading product is ready for Phase III of clinical trials. MEDIA ENCLOSURE: https://www.onemedplace.com/blog/wp-content/uploads/2011/10/bones.jpg
About this content
About
About the publisher
Proactive financial news and online broadcast teams provide fast, accessible, informative and actionable business and finance news content to a global investment audience. All our content is produced independently by our experienced and qualified teams of news journalists.
Proactive news team spans the world’s key finance and investing hubs with bureaus and studios in London, New York, Toronto, Vancouver, Sydney and Perth.
We are experts in medium and small-cap markets, we also keep our community up to date with blue-chip companies, commodities and broader investment stories. This is content that excites and engages motivated private investors.
The team delivers news and unique insights across the market including but not confined to: biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto and emerging digital and EV technologies.
Use of technology
Proactive has always been a forward looking and enthusiastic technology adopter.
Our human content creators are equipped with many decades of valuable expertise and experience. The team also has access to and use technologies to assist and enhance workflows.
Proactive will on occasion use automation and software tools, including generative AI. Nevertheless, all content published by Proactive is edited and authored by humans, in line with best practice in regard to content production and search engine optimisation.
No investment advice
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter. You understand...
FOR OUR FULL DISCLAIMER CLICK HERETeribone Treats Osteoporosis With Noninvasive Systematic Approach
Last updated: 17:53 14 Oct 2011 BST, First published: 21:53 14 Oct 2011 BST